Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of [3H]-Semaglutide in Healthy Males
NCT02060266Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2014
- Primary completion
- Apr 2014
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces up to 9 weeks. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02060266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02060266.